Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 1Plasmacytoma 1Neoplasm Metastasis 1Homologous Recombination Deficient Solid Tumors 1Drug-Related Side Effects and Adverse Reactions 1Colonic Neoplasms 1

Interventions

Fluorouracil 19Oxaliplatin 17Capecitabine 16Leucovorin 14Cisplatin 12Irinotecan 11Gemcitabine 11Drug Therapy 11Bevacizumab 10pembrolizumab 9Radiosurgery 9Cetuximab 9Docetaxel 8Everolimus 7spartalizumab 6Sunitinib 6Radiotherapy 6Paclitaxel 6Neoadjuvant Therapy 6Cyclophosphamide 6Trastuzumab 5S 1 (combination) 5Nivolumab 5Immunotherapy 5Immune Checkpoint Inhibitors 5Chemotherapy, Adjuvant 5Carboplatin 5palbociclib 4manganese chloride 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasm Metastasis × Drug Combinations × Clear all
NCT04138381 2023-03-27

SeliGIST

Grupo Espanol de Investigacion en Sarcomas

Phase 1/2 Unknown
30 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡